Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery (NCT01575548)

🧪 Interventions in This Study

• Pazopanib Hydrochloride (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Patient must be at least 18 years of age at the time of randomization
2. Patient must have pathologically confirmed renal cell carcinoma with a clear cell component; pure papillary and chromophobe histologies are excluded; there must be pathologic confirmation of metastatic disease in the resected metastasectomy specimen
3. Patient must have undergone nephrectomy or partial nephrectomy to remove primary renal cell carcinoma (at any time in the past)
4. Patient must have undergone surgical resection to remove one or more sites of metastatic disease, with successful removal of all known sites 2-12 weeks prior to randomization. Any number of prior metastasectomies may have been performed in the past, so long as the most recent procedure was within the 12 weeks of registration. The most recent procedure may be nephrectomy for a renal primary tumor
5. Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer \[AJCC\] 7th edition T1-4N0-1M1)
6. Positive surgical margins are permitted if the surgeon confirms complete resection of gross metastatic disease, and post-operative scans are negative
7. Patients presenting with metachronous disease may have distant metastases, regional lymph node or renal bed recurrence. Recurrences at a partial nephrectomy resection site are not eligible if it is the only site of disease
8. Patient must have no evidence of disease on post-operative imaging:
9. A computed tomography (CT) of the chest must be obtained within 4 weeks prior to randomization with or without contrast
10. A CT of the abdomen/pelvis must be obtained within 4 weeks prior to randomization with intravenous (IV) contrast (oral contrast may be added at the radiologist's discretion); an magnetic resonance imaging (MRI) of the abdomen/pelvis with gadolinium may be substituted for the CT if the CT with IV contrast is contra-indicated
11. An MRI of the brain with and without gadolinium must be done within 8 weeks prior to randomization; a CT of the brain with and without IV contrast is permitted if MRI is contra-indicated (i.e., pacemaker)
12. Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at the time of randomization

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (579 Sites)

Showing the first 25 of 579 sites.

• Fairbanks Memorial Hospital — Fairbanks, Alaska
• University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
• PCR Oncology — Arroyo Grande, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Epic Care-Dublin — Dublin, California
• Bay Area Breast Surgeons Inc — Emeryville, California
• Epic Care Partners in Cancer Care — Emeryville, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• Contra Costa Regional Medical Center — Martinez, California
• Alta Bates Summit Medical Center - Summit Campus — Oakland, California
• Bay Area Tumor Institute — Oakland, California
• Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
• Rocky Mountain Cancer Centers-Penrose — Colorado Springs, Colorado
• AdventHealth Porter — Denver, Colorado
• CommonSpirit Cancer Center Mercy — Durango, Colorado
• Mercy Medical Center — Durango, Colorado
• Mountain Blue Cancer Care Center — Golden, Colorado
• Grand Valley Oncology — Grand Junction, Colorado
• CommonSpirit Saint Anthony Hospital Cancer Center — Lakewood, Colorado
• Rocky Mountain Cancer Centers-Lakewood — Lakewood, Colorado

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Clear Cell Renal Cell Carcinoma

• Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma — Phoenix, Arizona
• A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors — Birmingham, Alabama
• Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer — Los Angeles, California
• Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors — Duarte, California
• Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma — Oklahoma City, Oklahoma

Explore by condition: All Clear Cell Renal Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.